JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details Textual) (USD $)	3 Months Ended		8 Months Ended	12 Months Ended	104 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013	Dec. 31, 2012	Mar. 31, 2013
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures				$ 6,000,000
Joint Venture Investments In Voting Common Ownership Units (in shares)				600,000
Joint Venture Method Investment Ownership Percentage				60.00%
Joint Venture Investments In Non Voting Preferred Ownership Units				5,000,000
Payments to Acquire Long-term Investments				3,300,000
Joint Venture Investments Common Ownership Units, Coventure (in shares)				400,000
Ownership Percentage Coventure				40.00%
Cash paid for assets of AzERx/CBI	0	0		0	4,058,000
Percentage Of Royalty Payment				3.00%
Development Activities Monthly Fee				63,000
Accounting and Administrative Monthly Fee				10,000
Investments In and Advance To Affiliates Additional Performance Measured Incentive Fee				250,000
Joint Venture Losses Recognition Criteria, Common Ownership Equity				0
Joint Venture, Operating Expenses, Inter Company Transactions	861,000				2,044,000
Joint Venture, Operating Expenses Allocated To Company			667,000		1,377,000
Percentage Of Non Royalty Income				15.00%
Exclusive License Agreement [Member]
Annual Maintenance Payments				25,000
Exclusive License Agreement [Member] | Maximum [Member]
Milestone Payments				1,000,000
Royalty Expense				5,000,000
Exclusive License Agreement [Member] | Minimum [Member]
Milestone Payments				50,000
Royalty Expense				1,000,000
Lipimetix [Member]
Cash paid for assets of AzERx/CBI				378,000	4,436,000
Corporate Joint Venture [Member]
Investments In and Advance To Affiliates Additional Performance Measured Incentive Fee				2,700,000
Voting Common Ownership Units [Member]
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures				1,000,000
Non Voting Preferred Ownership Units [Member]
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures				$ 5,000,000